Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Bivalirudin and Desmopressin Market size is projected to growing at around 5.1% CAGR during the forecast period i.e., between 2025-2037.
Increasing demand for bivalirudin is being driven by its application in the treatment of cancer and cardiovascular disease. In addition, rising incidences of cardiovascular diseases worldwide are expected to drive bivalirudin and desmopressin market growth during the forecast period. According to the World Health Organization, Cardiovascular disease is one of the leading causes of death worldwide. CVDs caused an estimated 17.9 million deaths in 2019, which accounted for 32% of all deaths worldwide. Furthermore, increasing demand for desmopressin owing to its use for nocturia and bedtime wetting is expected to drive global bivalirudin and desmopressin market growth. Desmopressin medicines have also been extensively used in conditions such as diabetes insipidus, which causes the body to produce excessive amounts of urine.
Bivalirudin is a synthetic residue compound that inhibits direct thrombin. Especially in people with severe chest pain or those undergoing angioplasty, it prevents the formation of blood clots. Also, heart attack patients who undergo percutaneous coronary intervention are treated with this drug. Likewise, desmopressin is an artificial replacement for vasopressin and acts by limiting the amount of water that is excreted in the urine. Moreover, awareness programs and initiatives regarding bedwetting and enuresis medical conditions are market trends expected to propel the demand for desmopressin during the forecast period. For instance, in September 2021, an organization launched a public awareness campaign to raise awareness about the problem of enuresis in children.
Bivalirudin and Desmopressin Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Percutaneous Coronary Interventions (PCI) Procedures Among Heart Patients - According to the American Heart Association, the number of percutaneous coronary interventions (PCI) in the United States reaches more than 600 000 each year, resulting in over USD 12 billion in healthcare expenditures. Percutaneous coronary intervention is a non-surgical procedure that involves placing a small stent into narrowed blood vessels in the heart caused by atherosclerosis using a thin flexible tube. Percutaneous Coronary Intervention (PCI) is becoming increasingly popular to treat acute coronary syndrome. With the use of anticoagulation therapy increasing during PCI, the risk of thrombotic complications is being reduced. This factor is expected to enlarge global bivalirudin and desmopressin market size during the forecast period.
- Growing Patients of Cancer Worldwide – According to the World Health Organization, cancer is the leading cause of death worldwide. In 2020, nearly 10 million people died from this disease. There are about 400 000 cases of cancer in children each year.
- Increasing Number Of Elderly People Suffering From Nocturia- In a study it was found that about 65% of men and 73% of women over 40 admitted getting up to use the bathroom at least once per night. It is estimated that approximately 50% of men who are 70 years old wake up at least twice a night to relieve themselves. The number of elderly people who suffer from nocturia may reach up to 80%.
- Higher Prevalence of Coronary Artery Disease Worldwide - According to the Centers for disease control and prevention in 2020, 382,820 people died from coronary heart disease. The incidence of CAD among adults aged 20 and over is about 7.2%. The proportion of deaths from CAD among adults younger than 65 years old is about 2 in 10.
- Globally Rising Patients of Diabetes - According to International Diabetes Federation, Diabetes affected approximately 537 million adults (20-79 years) in 2021. Diabetes is expected to affect 643 million people by 2030 and 783 million by 2045. A common sign and symptom of diabetes is excessive thirst and urination. People who suffer from diabetes urinate four to seven times a day on average. Thus, rising cases of diabetes worldwide are estimated to propel the demand for desmopressin during the forecast period.
Challenges
- High Cost Associated with the Bivalirudin Drug
- Health Concerns Such as Bleeding, Difficulty Breathing, and Sudden Numbness
- Unawareness Among People Regarding Less Medical Treatments
Bivalirudin and Desmopressin Segmentation
The global bivalirudin and desmopressin market is segmented and analyzed for demand and supply by application into percutaneous coronary intervention (PCI) procedures, percutaneous transluminal coronary angioplasty (PTCA) procedures, and others. Among these, the percutaneous coronary intervention (PCI) procedure segment is anticipated to capture the largest market size in the global bivalirudin and desmopressin market owing to the rising incidences of adverse cardiovascular (CVDs) and heart diseases among population. For instance, cardiovascular disease (CVD) was the leading cause of death in the United States in 2018, followed by stroke (17%), high blood pressure (11%), heart failure (9.5%), arteries diseases (3%), and other CVD (17.2%). PCI procedures are intended to reduce adverse cardiovascular diseases. PCI is further enhanced by antithrombotic and antiplatelet therapies as an adjunct to reduce MACE rates. This factor is expected to fuel the segment growth during the forecast period.
Our in-depth analysis of the global bivalirudin and desmopressin market includes the following segments:
|
By Application |
|
|
By End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Bivalirudin and Desmopressin Industry - Regional Synopsis
Regionally, the global bivalirudin and desmopressin market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is expected to hold largest revenue share by 2037, as coronary artery disease (CAD) prevalence among the population resulted in increasing percutaneous coronary intervention (PCI) procedures in the region. It was observed that nearly 960,000 percutaneous coronary intervention procedures are performed each year in the United States. Percutaneous coronary intervention (PCI) also known as angioplasty, is a procedure to open a blocked or narrowing artery. Moreover, increasing cases of cardiovascular diseases and heart diseases in the region are expected to drive bivalirudin and desmopressin market growth during the forecast period. For instance, there were approximately 695,000 deaths caused by heart disease in the United States in 2020.
Companies Dominating the Bivalirudin and Desmopressin Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Hainan Shuangcheng Pharmaceuticals Co. Ltd.
- AmbioPharm Inc.
- Abott India Limited (India)
- The Medicines Company
- Sun Pharmaceuticals Industries Limited
- Ferring Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Chengdu Shengnuo Biopharm Co. Ltd.
- ScinoPharm Taiwan Ltd
Recent Developments
- A definitive agreement has been signed between Pfizer Inc. and Global Blood Therapeutics, Inc. Pfizer Inc. will acquire GBT, a biopharmaceutical company devoted to discovering and developing life-changing treatments for isolated patient groups.
- AmbioPharm Inc., a leader in CDMO services for peptide APIs, announced the opening of its Shanghai campus and the appointment of members of its European executive team.
- Report ID: 266
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Bivalirudin and Desmopressin Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
